Organization
Sigilon Therapeutics
1 clinical trial
Clinical trial
A Phase 1/2 Open-Label, Sequential Dose-Escalation, Safety, Tolerability and Efficacy Study of SIG-005 in Adult Patients With Mucopolysaccharidoses 1 (MPS-1)Status: Withdrawn, Estimated PCD: 2022-12-13